Hepatic delivery of FXR mRNA via lipid nanoparticles enhances the efficacy of a low-dose FXR agonist in the treatment of MASLD

Nanomedicine: Nanotechnology, Biology and Medicine · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles